Exec Chat: Signifier Medical Investing In ‘Daytime-Only Treatments’ And Diagnostics For Sleep Apnea
The UK-based company is seeking to raise a further $100m in 2021 following the recent US clearance of its first product, a daytime-use neurostimulation device for snoring and mild obstructive sleep apnea.
You may also be interested in...
Approval for Boston Scientific’s TheraSphere offers further access to the therapy that, until now, has only been available under a humanitarian device exemption.
The deal combines two of the largest providers of sterilization and infection-prevention products to create a $4bn-plus-revenue business.
One of the few silver linings in a tumultuous year dominated by a global pandemic was the huge boost given to the diagnostics and telehealth sectors. But while new technologies for rapid testing for COVID-19 and remote monitoring tools dominated the headlines, there were also key developments in robotic surgery, early-stage cancer testing and cardiac arrhythmia treatment. Here are Medtech Insight’s most popular R&D stories in 2020.